Mild Cognitive Impairment - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Mild Cognitive Impairment - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Mild Cognitive Impairment - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 11, 2, 1 and 9 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Notable Market News

Therapix’s First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain

Companies Mentioned

AbbVie Inc AgeneBio Inc Avraham Pharmaceuticals Ltd Biogen Inc CereSpir Inc Eisai Co Ltd Eli Lilly and Co IntelGenx Corp Neuron Biopharma SA Octapharma AG Pfizer Inc Sage Therapeutics Inc SBI Pharmaceuticals Co Ltd Therapix Biosciences Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2ctsrc/mild_cognitive?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005412/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 09:58 AM/DISC: 09/17/2018 09:58 AM


Update hourly